A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo.

Condition studied

Non-segmental vitiligo

Investigational medicinal product(s)

Eligibility

Primary endpoint

Proportion of participants achieving ≥75% improvement from baseline in F-VASI at Week 24.

Endpoint detail

Percent change from baseline in the F-VASI at Week 24, Percent change from baseline in the T-VASI at Week 24, Proportion of participants achieving ≥50% improvement from baseline in F-VASI at Week 24, Proportion of participants achieving ≥50% improvement from baseline in T-VASI at Week 24